# Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer

> **NCT00965718** · PHASE2 · COMPLETED · sponsor: **GC Cell Corporation** · enrollment: 20 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** Activated T lymphocyte

## Key facts

- **NCT ID:** NCT00965718
- **Lead sponsor:** GC Cell Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00965718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00965718, "Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00965718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*